CD8A and neoplasm: In the immune competent “hot tumor” CT26/BALBc syngeneic model, RXC004 synergized with anti-PD-1 treatment to decrease immunosuppressive regulatory T cells, and increase the ratio of cytotoxic CD8 T cells to regulatory T cells within the tumor.